Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

Generalisation from phase III clinical trials: survival, quality of life, and health economics.

Fayers PM, Hand DJ.

Lancet. 1997 Oct 4;350(9083):1025-7. No abstract available.

PMID:
9329528
2.

Factors to consider when designing phase III clinical trials involving economic evaluations.

van Enckevort PJ, TenVergert EM, Kingma J, Ko√ęter GH, Rutten FF.

Percept Mot Skills. 1999 Dec;89(3 Pt 2):1059-72. Review.

PMID:
10710753
3.

Effect of a US National Institutes of Health programme of clinical trials on public health and costs.

Johnston SC, Rootenberg JD, Katrak S, Smith WS, Elkins JS.

Lancet. 2006 Apr 22;367(9519):1319-27. Review.

PMID:
16631910
4.

Challenges in the design and conduct of phase III brain tumor therapy trials.

Perry JR, DeAngelis LM, Schold SC Jr, Burger PC, Brem H, Brown MT, Curran WJ, Scott CB, Prados MD, Kaplan R, Cairncross JG.

Neurology. 1997 Oct;49(4):912-7. Review. No abstract available.

PMID:
9339667
5.

Economic analysis during phase III clinical trials: who, what, when, where, and why?

Bennett CL, Westerman IL.

Oncology (Williston Park). 1995 Nov;9(11 Suppl):169-75. Review.

6.

'Health Economics' and the evolution of economic evaluation of health technologies.

Hutton J.

Health Econ. 2012 Jan;21(1):13-8. doi: 10.1002/hec.1818. Review. No abstract available.

PMID:
22147623
7.

Medical economics and the assessment of value in cardiovascular medicine: Part II.

Mark DB, Hlatky MA.

Circulation. 2002 Jul 30;106(5):626-30. Review. No abstract available.

8.

Cost-effectiveness as an outcome in randomized clinical trials.

Hlatky MA, Owens DK, Sanders GD.

Clin Trials. 2006;3(6):543-51. Review.

PMID:
17170039
9.

Impact of quality of life outcomes on clinical practice.

Ganz PA.

Oncology (Williston Park). 1995 Nov;9(11 Suppl):61-5. Review.

10.

Economic analysis alongside clinical trials: practical considerations. The Economics Workgroup.

Drummond M, O'Brien B.

J Rheumatol. 1995 Jul;22(7):1418-9. Review. No abstract available.

PMID:
7562789
11.

Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.

Brundage MD, Mackillop WJ.

J Clin Epidemiol. 1996 Feb;49(2):183-92. Review.

PMID:
8606319
12.

A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

Staidle JP, Dabade TS, Feldman SR.

Expert Opin Pharmacother. 2011 Sep;12(13):2041-54. doi: 10.1517/14656566.2011.590475. Epub 2011 Jul 8. Review.

PMID:
21736530
13.

[Economic impact of cardiac resynchronization therapy in patients with heart failure. Available evidence and evaluation of the CRT-Eucomed model for analysis of cost-effectiveness].

Fattore G, Landolina M, Bontempi L, Cacciatore G, Curnis A, Gulizia M, Padeletti L, Mazzei L, Tavazzi L; Gruppo di Studio congiunto Federazione Italiana di Cardiologia-Assobiomedica di Cardiologia-Assobiomedica "Valutazione del Medello CRT-Eucomed".

Ital Heart J Suppl. 2005 Dec;6(12):796-803. Review. Italian.

PMID:
16444923
14.

Simultaneous analysis of quality of life and survival data.

Billingham LJ, Abrams KR.

Stat Methods Med Res. 2002 Feb;11(1):25-48. Review.

PMID:
11923992
15.

Quality of life and clinical trials.

[No authors listed]

Lancet. 1995 Jul 1;346(8966):1-2. Review. No abstract available.

PMID:
7603136

Supplemental Content

Support Center